Simulations Suggest Pharmacological Methods for Rescuing Long-Term Potentiation
Paul Smolen, Douglas A. Baxter, John H. Byrne

TL;DR
This study uses computational modeling to identify potential pharmacological strategies, such as combining phosphodiesterase and deacetylase inhibitors, to rescue long-term potentiation deficits linked to cognitive disorders like RTS.
Contribution
It demonstrates that paired drug effects can synergistically restore LTP in a model of cognitive impairment, guiding potential therapeutic approaches.
Findings
Paired parameter variations can restore LTP without affecting basal synaptic weight.
Synergistic effects observed with combined phosphodiesterase and deacetylase inhibitors.
Modeling suggests promising drug combinations for cognitive disorder therapies.
Abstract
Congenital cognitive dysfunctions are frequently due to deficits in molecular pathways that underlie synaptic plasticity. For example, Rubinstein-Taybi syndrome (RTS) is due to a mutation in cbp, encoding the histone acetyltransferase CREB-binding protein (CBP). CBP is a transcriptional co-activator for CREB, and induction of CREB-dependent transcription plays a key role in long-term memory (LTM). In animal models of RTS, mutations of cbp impair LTM and late-phase long-term potentiation (LTP). To explore intervention strategies to rescue the deficits in LTP, we extended a previous model of LTP induction to describe histone acetylation and simulated LTP impairment due to cbp mutation. Plausible drug effects were simulated by parameter changes, and many increased LTP. However no parameter variation consistent with a biochemical effect of a known drug fully restored LTP. Thus we examined…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
